Document is current
Any future updates will be listed below
-
Authors
Perton, F. T.
Pouw, J. N.
Spierings, J.
Kors, D. N.
Concepcion, A. N.
Bekker, C. P. J.
Vonkeman, H. E.
Mooij, S. C.
Schipper, L. G.
Herman, A.
Vreugdenhil, S. A.
,
Bhansing, Kavish J.
Bisoendial, Radjesh J.
van Bijnen, Sandra T.A.
van Bon, Lenny
Comarniceanu, Antoaneta C.
Herman, Amin
Jahangier, Nazira
Jansen, Tim L.T.A.
Kadir, Sylvana W.
Kok, Marc R.
van Kuijk, Arno W. R.
Leijten, Emmerik F.A.
Mooij, Shasti C.
Schipper, Lydia G.
van Tubergen, Astrid M.
Vonkeman, Harald E.
Vreugdenhil, Simone A.
Wijngaarden, Siska
Mastbergen, S. C.
Welsing, P. M. J.
-
Funding
Funding for this research was provided by:
Pfizer Netherlands
Health~Holland (LSHM17074)
- License Information
-
More Information
Article History
Received: 6 February 2026
Accepted: 14 May 2026
First Online: 28 May 2026
Declarations
Ethics approval and consent to participate: Reported in open protocol publication [ ].
Consent for publication: Not applicable.
Competing interests: HEV: paid consultant for Abbvie, Novartis, Pfizer, UCB, Johnson and Johnson. Financial grants from (pharmaceutical) companies: Galapagos and Boehringer Ingelheim. AWRVK: Paid consultant for Janssen, Novartis and UCB. Financial grants from Novartis and UCB.
